Healthcare entity
Every one of those 2 sits in a single category, market-trends. Apogee Therapeutics is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across an 18-day span, the pace is roughly 0.8 stories per week. Source depth averages 2 original sources per story, versus 3.2 across the same-window beat baseline.
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, market-trends. Apogee Therapeutics is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across an 18-day span, the pace is roughly 0.8 stories per week. Source depth averages 2 original sources per story, versus 3.2 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 5.9 in the same window. We currently track 2 Healthcare stories that mention Arcturus Therapeutics, published between March 2, 2026 and March 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 378 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Arcturus Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Q4 Earnings Release
Both companies scheduled to report full-year 2025 financial results.
ARCT-032 Phase 1b
Arcturus releases positive interim data for Cystic Fibrosis candidate.
Kostaive Approval
Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.
Apogee Therapeutics and Arcturus Therapeutics faced simultaneous downgrades and initiations in a single trading session, highlighting a sharp divide in analyst sentiment. This volatility reflects broader market uncertainty regarding clinical-stage biotech valuations and the specific pipelines of these immunology and mRNA specialists.
Source: benzinga.com · benzinga.com
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.
Source: Seeking Alpha · Seeking Alpha
Arcturus Therapeutics is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
